Metabolic biomarkers for Alzheimer's disease: A mini review
Authors:
Open Access
- 27 October 2023
- journal article
- Published by Scholar Media Publishing in Metabolism and Translational Medicine
- Vol. 1
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia worldwide, which characterized by progressive cognitive decline, memory impairment, and changes in behavior and personality. The prevalence of AD is expected to rise significantly in the coming decades due to the aging population, making it a major public health concern. Mounting evidence suggests that metabolic dysregulation plays a critical role in the pathogenesis of AD. In this mini review, we provide an overview of the current understanding of the interplay between metabolism and AD. Specifically, we explore the dysregulation of glucose metabolism, lipid metabolism, amino acid metabolism, and nitrogen oxide synthesis pathways in AD. These metabolic alterations have been identified as potential biomarkers for early diagnosis and prognosis of AD. Additionally, we discuss the current status of research in this field, including the advancements in metabolomics and imaging techniques that have allowed for the identification and validation of metabolic biomarkers.Keywords
This publication has 9 references indexed in Scilit:
- Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promiseThe FEBS Journal, 2022
- Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Functional Metabolic Mapping Reveals Highly Active Branched-Chain Amino Acid Metabolism in Human Astrocytes, Which Is Impaired in iPSC-Derived Astrocytes in Alzheimer's DiseaseFrontiers in Aging Neuroscience, 2021
- APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approachesThe Lancet Neurology, 2021
- APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoidsNature Communications, 2020
- The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeuticsActa Neuropathologica, 2020
- Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approachesThe Lancet Neurology, 2020
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomersJournal of Clinical Investigation, 2012
- Iron, brain ageing and neurodegenerative disordersNature Reviews Neuroscience, 2004